Boston Scientific announces results for third quarter 2026
Boston Scientific posted Q3 2026 net sales of $5.138 billion, up just 1.5% on a reported, operational and organic basis, with GAAP EPS of $0.40 versus $0.51 a year ago and adjusted EPS of $0.73 versus $0.75. Management guided Q4 2026 net sales to DECLINE 3.0% to 1.0% on a reported and organic basis, with adjusted EPS of $0.77-$0.79, and narrowed full-year adjusted EPS guidance to $3.16-$3.18. CEO Mike Mahoney flagged a challenging year dominated by recovery from the August 2026 cybersecurity incident, which the company lists as an ongoing operational and financial risk.
Key figures
- Eps
- 0.4
- Revenue
- 5138000000
- Guidance
- FY26 net sales growth ~4.25% reported / ~3.75% organic, adjusted EPS $3.16-$3.18; Q4 net sales decline of (3.0)% to (1.0)% reported and organic, adjusted EPS $0.77-$0.79
- Revenue Yoy
- 1.5%
- Adjusted eps
- 0.73
- Gross profit
- 3428000000
- Gaap net income
- 582000000
- Operating income
- 828000000
- Medsurg growth organic
- 0.7%
- Q4 guided sales growth
- (3.0)% to (1.0)% reported and organic
- Adjusted eps prior year
- 0.75
- Cardiovascular growth organic
- 1.9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.